SCHEMBL2291163

SCHEMBL2291163

Cc1cccc(C)c1Nc1ccc(F)n2ccnc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 4/20 0.40
▸ GAA P10253 9/20 0.39
▸ MAPT P10636 8/20 0.39
▸ HTT P42858 2/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ RAPGEF4 Q8WZA2 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ FLT1 P17948 1/20 0.35
▸ CDK8 P49336 1/20 0.35
▸ CDK9 P50750 1/20 0.35
▸ LIMK1 P53667 1/20 0.35
▸ ROCK1 Q13464 1/20 0.35
▸ CLK4 Q9HAZ1 1/20 0.35
▸ PTGS2 P35354 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2292833 0.77 PTGS2 (0.42) SRCGAARAPGEF4PTGS2LCK
SCHEMBL2289473 0.76 SRC (0.50) SRCGAAMAPTHTTSMN1; SMN2
SCHEMBL2295452 0.72 SRC (0.44) SRCGAAMAPTSMN1; SMN2RAPGEF4
SCHEMBL2285934 0.68 PTGS2 (0.44) SRCRAPGEF4PTGS2LCK
SCHEMBL2659311 0.67 CCNE1 (0.38) CDK8ROCK1CYP3A4
SCHEMBL1921293 0.66 RAPGEF4 (0.57) MAPTHTTRAPGEF4KMT2APTGS2
SCHEMBL2291937 0.66 SRC (0.40) SRCGAAMAPTRAPGEF4MAPK1
SCHEMBL3946708 0.66 ACHE (0.50) GAAMAPTHTTSMN1; SMN2RAPGEF4
SCHEMBL5838736 0.65 SRC (0.48) SRCGAAMAPTRAPGEF4KMT2A
SCHEMBL12574970 0.65 SRC (0.48) SRCGAAMAPTHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258151-B2 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors MERCK PATENT GMBH (DE) 2012-09-04 — — US disclosed
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GESELLSCHAFT (DE) 2011-08-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS GLP1R, SLC5A1, SLC5A2 SRC 1265/4885GAA 1202/4885MAPT 1138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback